Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma

Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial testing the regimen as an adjuvant therapy for patients whose melanoma has been surgically removed. While Opdualag is still projected to reach blockbuster status, it could face competition from a Regeneron Pharmaceuticals drug. The post Bristol Myers Squibb Cancer Immunotherapy Flunks a…

Read More

A Dose of Love: The Winning Health Policy Valentines

Nothing sweeps us off our feet like a health policy valentine. Readers showed their love this season, writing poetic lines about surprise medical bills, bird flu, the cost of health care, and more.  Here are some of our favorites, starting with the grand prize winner, whose entry was turned into a cartoon by staff illustrator…

Read More